722 related articles for article (PubMed ID: 15217805)
41. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
[TBL] [Abstract][Full Text] [Related]
42. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
43. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells.
Wells SM; Holian A
Am J Respir Cell Mol Biol; 2007 May; 36(5):520-8. PubMed ID: 17158357
[TBL] [Abstract][Full Text] [Related]
44. Acute and conditioned hypoxic tolerance augmented by endothelial nitric oxide synthase inhibition in mice.
Song MY; Zwemer CF; Whitesall SE; D'Alecy LG
J Appl Physiol (1985); 2007 Feb; 102(2):610-5. PubMed ID: 17068215
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T
Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680
[TBL] [Abstract][Full Text] [Related]
46. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
47. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
[TBL] [Abstract][Full Text] [Related]
48. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
49. Permissive role of nitric oxide in macula densa control of renin secretion.
Castrop H; Schweda F; Mizel D; Huang Y; Briggs J; Kurtz A; Schnermann J
Am J Physiol Renal Physiol; 2004 May; 286(5):F848-57. PubMed ID: 15075180
[TBL] [Abstract][Full Text] [Related]
50. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.
Tanaka M; Sydow K; Gunawan F; Jacobi J; Tsao PS; Robbins RC; Cooke JP
Circulation; 2005 Sep; 112(11):1549-56. PubMed ID: 16144995
[TBL] [Abstract][Full Text] [Related]
51. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats.
Takemoto M; Egashira K; Usui M; Numaguchi K; Tomita H; Tsutsui H; Shimokawa H; Sueishi K; Takeshita A
J Clin Invest; 1997 Jan; 99(2):278-87. PubMed ID: 9005996
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
Kielstein JT; Impraim B; Simmel S; Bode-Böger SM; Tsikas D; Frölich JC; Hoeper MM; Haller H; Fliser D
Circulation; 2004 Jan; 109(2):172-7. PubMed ID: 14662708
[TBL] [Abstract][Full Text] [Related]
53. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Napoli C; Sica V; de Nigris F; Pignalosa O; Condorelli M; Ignarro LJ; Liguori A
Am Heart J; 2004 Jul; 148(1):e5. PubMed ID: 15215814
[TBL] [Abstract][Full Text] [Related]
54. Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice.
Sanz MJ; Hickey MJ; Johnston B; McCafferty DM; Raharjo E; Huang PL; Kubes P
Br J Pharmacol; 2001 Sep; 134(2):305-12. PubMed ID: 11564648
[TBL] [Abstract][Full Text] [Related]
55. Novel mechanism of salt-induced glomerular injury: critical role of eNOS and angiotensin II.
Nakamura T; Kataoka K; Tokutomi Y; Nako H; Toyama K; Dong YF; Koibuchi N; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2011 Aug; 29(8):1528-35. PubMed ID: 21720272
[TBL] [Abstract][Full Text] [Related]
56. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats.
Fu YF; Xiong Y; Guo Z
Eur J Pharmacol; 2005 Jan; 508(1-3):167-75. PubMed ID: 15680268
[TBL] [Abstract][Full Text] [Related]
57. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats.
De Gennaro Colonna V; Bonomo S; Ferrario P; Bianchi M; Berti M; Guazzi M; Manfredi B; Muller EE; Berti F; Rossoni G
Eur J Pharmacol; 2007 Feb; 557(2-3):178-85. PubMed ID: 17258196
[TBL] [Abstract][Full Text] [Related]
58. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.
von Leitner EC; Klinke A; Atzler D; Slocum JL; Lund N; Kielstein JT; Maas R; Schmidt-Haupt R; Pekarova M; Hellwinkel O; Tsikas D; D'Alecy LG; Lau D; Willems S; Kubala L; Ehmke H; Meinertz T; Blankenberg S; Schwedhelm E; Gadegbeku CA; Böger RH; Baldus S; Sydow K
Circulation; 2011 Dec; 124(24):2735-45. PubMed ID: 22082678
[TBL] [Abstract][Full Text] [Related]
59. Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina.
Closs EI; Ostad MA; Simon A; Warnholtz A; Jabs A; Habermeier A; Daiber A; Förstermann U; Münzel T
Biochem Biophys Res Commun; 2012 Jun; 423(2):218-23. PubMed ID: 22609206
[TBL] [Abstract][Full Text] [Related]
60. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Yilmaz MI; Saglam M; Sonmez A; Caglar K; Cakir E; Kurt Y; Eyileten T; Tasar M; Acikel C; Oguz Y; Vural A; Yenicesu M
Blood Purif; 2007; 25(4):327-35. PubMed ID: 17709915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
